Loy Britto presently serves as the CEO of Healthy Airways LLC, where he offers consultancy services to the pharmaceutical industry, specializing in the development, registration, and commercialization of Orally Inhaled and Nasal Drug Products (OINDP). With profound technical, scientific, and practical expertise, Loy advises clients ranging from pharmaceutical companies, device component manufacturers to suppliers of excipients for inhaled products. Additionally, he holds the position of Chief Scientific Officer at Sonohaler.
Prior to his role at Healthy Airways LLC, Loy worked for over three decades at GlaxoSmithKline (GSK). Throughout his tenure at GSK, he contributed extensively to the development and commercialization of inhaled products, spanning various delivery platforms such as metered dose inhalers (MDIs), dry powder inhalers (DPIs), and smart mist inhalers (SMIs). He was employed at GSK facilities in the United States, France, and the United Kingdom, overseeing the entire lifecycle of products from early-stage development to global commercialization.
During his tenure at GSK, Loy held the position of Global Technical Product Owner in the Manufacturing Science and Technology organization, where he spearheaded the development and commercialization of GSK’s worldwide MDI product portfolio. His responsibilities encompassed formulations, device components, analytical testing, manufacturing processes, and regulatory submissions. Loy served as a primary technical liaison with suppliers worldwide for critical device components, including valves, actuators, canisters, and dose counters. Furthermore, he served as GSK’s subject matter expert for the development of Ventolin MDI with low Global Warming Potential (GWP) propellants.
Loy’s role extended to managing cross-functional product development teams globally, ensuring the seamless commercialization of GSK MDI products, maintaining supply to all markets, and navigating product lifecycle changes alongside associated global regulatory submissions. He has authored over 30 global regulatory submissions, including container closure sections, for GSK MDI products such as Ventolin, Seretide, Advair, Flovent, Flixotide, Serevent, and Becotide.
Prior to joining GSK, Loy spent seven years at IBM as an Advisory Engineer, and three years at Atlantic Richfield Co (ARCO) as a Senior Engineer. He holds a Ph.D. in Materials Engineering from the Massachusetts Institute of Technology (MIT) and holds a broad portfolio of more than 30 international patents and patent applications covering innovations in inhaled products and laser printers.
